REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai > Cyclopeptides > 3 Or 4 Peptide Repeating Units In Known Peptide Chain 3 Or 4 Peptide Repeating Units In Known Peptide Chain3 Or 4 Peptide Repeating Units In Known Peptide Chain patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021352 - Prevention and treatment of hearing disorders Compositions, and methods of use thereof, are provided for the prevention, treatment or alleviation of symptoms of hearing are provided. Embodiments of the methods employ zonisamide as the sole active pharmaceutical agent or a combination of zonisamide and another pharmaceutical agent, such as an antioxidant, a NMDA antagonist, an SSRI ... 01/25/07 - 20070021351 - Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor Compositions and therapeutic combinations are provided including at least one compound selected from the group consisting of compounds of Formulae I to XXVI as defined herein as well as methods of treatment, prevention or amelioration of one or more symptoms of hepatitis C, treating disorders associated with HCV virus, modulating ... 01/11/07 - 20070010456 - Therapeutic agents for low hdl-cholesterolemia The present invention is to provide an agent for low HDL-cholesterolemia, a prophylactic and/or therapeutic antiarteriosclerosis agent as well as a method for preventing and treating low HDL-cholesterolemia, arteriosclerosis and their related diseases or disorders, with emphasis given to improvement in HDL, without resorting to genetic engineering technology. Further, the ... 01/11/07 - 20070010455 - Hepatitis c virus inhibitors The present disclosure relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. ... 01/11/07 - 20070010454 - Method for treating tumor cells resulting in minimal liver toxicity A method for treating tumor cells resulting in minimal liver toxicity. An illustrative embodiment includes a method for inhibiting growth of a tumor in a mammal, comprising contacting tumor cells which have tyrosinase activity or P450 activity with 4-t-butoxyphenol, a cytotoxic phenolic composition administered at a dose sufficient to induce ... 01/11/07 - 20070010453 - Prodrugs of gaba analogs, compositions and uses thereof The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing ... 01/04/07 - 20070004642 - Oxadiazole derivatives and drugs containing these derivatives as the active ingredient The compound of formula (I) has an inhibitory activity against cysteine protease and therefore it is useful as an agent for the prophylaxis and/or treatment of inflammatory diseases, diseases induced by apoptosis, diseases induced by disorders of immune responses, autoimmune diseases, diseases induced by decomposition of proteins which compose organism, ... 01/04/07 - 20070004641 - Cognitive enhancement and cognitive therapy using glycyl-l-2-methylprolyl-l-glutamate This invention provides compounds, compositions and methods for treating loss of cognitive function in animals that results from aging. In particular, compounds of this invention can stimulate neural cell growth, increased amounts of cells containing a key enzyme needed for production of the cholinergic neurotransmitter, and can improve memory and ... 01/04/07 - 20070004640 - Treatment of dry eye The present invention relates to methods to treat dry eye in a mammal by intraocularly administering a composition comprising a peptide. ... 01/04/07 - 20070004639 - Methods and compositions for treating parkinson's disease The invention as disclosed herein provides pharmaneutical compositions and methods for treating, ameliorating, or preventing the symptoms of Parkinson's Disease. The pharmaneutical compositions of the invention contain in an effective amount a first and a second composition, the first composition comprises an effective amount of one or more phosphatidylcholine formulations ... 01/04/07 - 20070004638 - Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide Crystalline polymorphs of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide which are useful as pharmaceutical agents are disclosed. Methods of production and isolation of these polymorphs and pharmaceutical compositions which include these polymorphs and pharmaceutical methods of treatment are also disclosed. The crystalline polymorphs of the present invention are useful as they act directly ... 01/04/07 - 20070004637 - Peptide derivatives having beta-secretase inhibitory activity in which Z is —NH, -Asp-Ala-NH—, -Asp-Ala-, -Asp-NH—, or the like; L is a 5-to 10-membered ring optionally containing a heteroatom and/or unsaturated bond; X is —COOH, tetrazole ring, or the like; Y is hydrogen, —COOH, or the like; and k is an integer of 1 to 4; and R1, ... 01/04/07 - 20070004636 - Method of degrading transcriptional factors of saccharometabolism-associated gene, method for inhibiting the degradation, and agent for inhibiting degradation and degradation inhibitor Based on the finding that m-calpain or μ-calpain degrades hepatocyte nuclear factor 4α (HNF-4α), hepatocyte nuclear factor 1α (HNF-1α) and insulin promoter factor 1 (IPF-1), which form transcription factor networks involved in expression of glucose metabolism-related genes in pancreatic β cells, the following have been provided: a method for degradation ... 12/28/06 - 20060293247 - Trh-like peptide derivatives as inhibitors of the trh-degrading ectoenzyme Y is —(CH2)n— where n is 0, 1, 2 or 3 provided that when R2 and R3 form part of the ring n is 0; and pharmaceutically acceptable salts thereof. ... 12/21/06 - 20060287250 - Methods for synthesis of acyloxyalkyl derivatives of gaba analogs The synthesis of 1-(acyloxy)-alkyl carbamates of GABA analogs from 1-haloalkyl carbamates of GABA analogs are described. Also described are new 1-haloalkyl carbamates of GABA analogs. ... 12/21/06 - 20060287249 - Crystalline forms There is provided EtO2C—CH2—(R)Cgl-Aze-Pab-OH, or a pharmaceutically-acceptable salt thereof, in a form which is substantially crystalline. It has been found that crystalline forms of EtO2C—CH2—(R)Cgl-Aze-Pab-OH have a high chemical and solid slate stability when compared to amorphous forms of the compound. ... 12/21/06 - 20060287248 - Asymmetric dosing methods A method of treating, preventing or ameliorating one or more symptoms of hepatitis C, or inhibiting cathepsin activity, in a subject is provided, in which at least one compound (e.g., a HCV protease inhibitor) is administered in one or more discrete dosages over a twenty-four hour time interval in an ... 12/14/06 - 20060281689 - Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period Methods are provided for using at least one novel hepatitis C (“HCV”) protease inhibitor in combination with at least one antiviral and/or immunomodulatory agent, which is different from the at least one HCV protease inhibitor, for treating a wide variety of diseases or disorders associated with hepatitis C virus by ... 12/14/06 - 20060281688 - Administration of hcv protease inhibitors in combination with food to improve bioavailability Methods of treating, preventing or ameliorating one or more symptoms of hepatitis C in a subject comprising the step of administering at least one HCV protease inhibitor in combination with food are provided. Also provided are methods of increasing bioavailability of an HCV protease inhibitor and methods of increasing serum ... 12/07/06 - 20060276409 - Antibacterial agents R1 represents hydrogen, or C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms; R2 represents a group R10—(X)n-(ALK)m- wherein R10 represents hydrogen, or a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, ... 12/07/06 - 20060276408 - Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins There are disclosed β-sheet mimetics and methods relating to the same for imparting or stabilizing the β-sheet structure of a peptide, protein or molecule. In one aspect, β-sheet mimetics are disclosed having utility as protease inhibitors in general and, more specifically, as serine protease inhibitors such as thrombin, elastase and ... 12/07/06 - 20060276407 - Methods of treating hepatitis c virus Compositions and therapeutic combinations are provided including at least one compound selected from the group consisting of compounds of Formulae I to XXVI as defined herein as well as methods of treatment, prevention or amelioration of one or more symptoms of hepatitis C, treating disorders associated with HCV virus, modulating ... 12/07/06 - 20060276406 - Methods of treating hepatitis c virus Methods for preventing, ameliorating or treating one or more symptoms of Hepatitis C virus (HCV), modulating HCV protease activity and/or inhibiting cathepsin activity in a subject, wherein the methods comprise administering to a subject in need of such treatment a dosage formulation containing at least one compound of Formulae I-XXVI ... 12/07/06 - 20060276405 - Methods for treating hepatitis c Methods of treating hepatitis C are provided comprising using a therapeutically effective amount of at least one novel hepatitis C (“HCV”) protease inhibitor or, alternatively, at least one antiviral or immuno-modulating HCV agent, which is not an HCV protease inhibitor, for a first treatment period. Subsequently, a combination of the ... 12/07/06 - 20060276404 - Medicaments and methods combining a hcv protease inhibitor and an akr competitor Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations of a hepatitis C virus (HCV) protease inhibitor and an aldo-keto reductase (AKR) competitor, for concurrent or consecutive administration in treating, preventing, or ameliorating one or more symptoms of HCV, treating disorders associated with HCV, or inhibiting cathepsin ... 11/30/06 - 20060270607 - Pharmaceutical combinations The present invention provides novel pharmaceutical combinations and their use in anti-thrombotic therapy. ... 11/23/06 - 20060264379 - Bir domain binding compounds in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains. In particular, the compounds are useful in treating proliferative disorders such as cancer ... 11/09/06 - 20060252700 - Immunomodulator An immunomodulator is provided which is capable of oral intake for improvement, treatment and prevention of human immunological diseases and which is used to treat, improve and prevent human immunological diseases, especially, autoimmune diseases and allergic diseases such as hepatic cirrhosis, hepatitis, diabetes, inflammatory bowel diseases, chronic rheumatoid arthritis, asthma ... 11/09/06 - 20060252699 - Method for lowering serum homocysteine The present invention provides a method for reducing the amount of homocysteine in the blood of an individual. The method comprises administering to the individual a composition comprising a homocysteine lowering agent in an amount effective to lower the amount of homocysteine in the blood of the individual. The homocysteine ... 11/02/06 - 20060247178 - Mitotic kinesin inhibitors and methods of use thereof This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders. ... 10/26/06 - 20060241057 - Peptidyl allyl sulfones The present disclosure provides compositions for inhibiting proteases, methods for synthesizing the compositions, and methods of using the disclosed protease inhibitors. Aspects of the disclosure include peptidyl allyl sulfone compositions that inhibit proteases, for example cysteine proteases, either in vivo or in vitro. ... 10/12/06 - 20060229253 - Pentapeptide compounds and uses related thereto Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieties, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reaction site for joining to a targeting agent, e.g., an antibody, as ... 10/05/06 - 20060223760 - Compositions and methods for treatment of cancer The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a ... 10/05/06 - 20060223759 - Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof wherein the groups R1 to R15, A, B, L, i as well as X1-X4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases. ... 09/28/06 - 20060217320 - Soft gel formulations for saquinavir The present invention describes a pharmaceutical composition with increased bioavailability, which is suitable for preparing microcapsules for the therapeutic administration of a protease inhibitor. It is also described a process for preparing a pharmaceutical composition with increased bioavailability, suitable to prepare concentrate pharmaceutical compositions comprising retroviral protease inhibitors. ... 09/28/06 - 20060217319 - Method for modulating nod1 activity, use of a mtp related molecule for modulating nod1 activity, and therapeutic applications thereof A method for modulating Nod1 activity wherein said method comprises the steps of providing cells expressing a functional Nod1; and bringing said cells into contact with a molecule related to compositions comprising a molecule related to MTP and use of a molecule related to MTP for modulating inflammation and/or apoptosis. ... 09/28/06 - 20060217318 - Ace inhibitory peptides from plant materials Improved processes are provided for preparing ACE inhibitory peptide containing hydrolysates from a plant material such as a seed meal or flour. In one embodiment, the seed meal or flour is extracted with an organic solvent prior to digestion. Also provided are ACE inhibitory peptides Val-Ser-Val and Phe-Leu. ... 09/21/06 - 20060211629 - Inhibitors of serine proteases, particularly hcv ns3-ns4a protease The present invention relates to compounds of formula I or formula Ia or pharmaceutically acceptable salts thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as ... 09/21/06 - 20060211628 - Treatment of multiple sclerosis with brain targeted anti oxidant compounds A method of treating multiple sclerosis, the method comprises administering to a subject in need thereof a therapeutically effective amount of a compound, the compound having: (a) a combination of molecular weight and membrane miscibility properties for permitting the compound to cross the blood brain barrier of the organism; (b) ... 09/14/06 - 20060205673 - 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives wherein the substituents and symbols are defined as indicated in the description, to processes for the preparation thereof, to medicaments comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans. ... 09/14/06 - 20060205672 - Novel peptides as ns3-serine protease inhibitors of hepatitis c virus The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. ... 09/14/06 - 20060205671 - Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury Methods and compositions including combined use of a serine protease inhibitor and adenosine when administered as a single pharmaceutical composition, concomitantly or sequentially in any order to a living subject for preventing organ ischemia or reperfusion injury. The methods and compositions disclosed herein can be used in such procedures as ... 09/07/06 - 20060199773 - Crystalline forms of (1r,2s)-n-[(1,1-dimethylethoxy)carbonyl]-3-methyl-l-valyl-(4r)-4-[(6-methoxy-1-isoquinolinyl)oxy]-l-prolyl-1-amino-n-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt The present disclosure generally relates to crystalline forms of (1R,2S)-N-[(1,1 -dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide. The present disclosure also generally relates to a pharmaceutical composition comprising a crystalline form, as well of methods of using a crystalline form in the treatment of Hepatitis C and methods for obtaining such crystalline form. ... 09/07/06 - 20060199772 - Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy The present invention relates to the use of a proteasome inhibitor for the manufacture of a medicament for the prevention, onset therapy, acute therapy and/or regression of diseases associated with endothelial dysfunction. The present invention also relates to the use of a proteasome inhibitor as a low-dose treatment. ... 08/24/06 - 20060189544 - Integrin-mediated drug targeting The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to αvβ3 integrin antagonists via preferred linking units. The preferred linking units guarantee serum stability of the conjugate of cytostatic and αvβ3 integrin antagonist and at the same time the desired intracellular action in ... 08/24/06 - 20060189543 - Compositions and methods for the treatment of leukemia A method for the treatment of leukemia by internal administration of a composition including one or more compounds that inhibit cytokines and one or more antioxidants, optionally formulated in a pharmaceutically acceptable carrier. The composition of the present invention may further include optional ingredients such as flavonoids, flavonoid derivatives, and ... 08/24/06 - 20060189542 - Preventive or therapeutic composition for viral infectious disease The invention provides a composition for preventing or treating infectious diseases of a virus belonging to the Coronavirus family or Flavivirus family, the composition containing one or more substances selected from reduced glutathione or oxidized glutathione or pharmaceutically acceptable salts thereof and catechin, and a composition for preventing or treating ... 08/17/06 - 20060183691 - Anti-hypertensive molecules and process for preparation thereof The present invention relates to novel anti-hypertensive molecules. The present invention also provides a process for the preparation of novel antihypertensive molecules. The present invention particularly relates to the preparation of novel Angiotensin Converting Enzyme Inhibitors (ACEI) with prolonged activity. ACE inhibitors play an important role in Renin-Angiotensin-Aldosteron system (RAAS) ... 08/17/06 - 20060183690 - Anti-hypertensive dietary supplement An anti-hypertensive fish protein hydrolysate is provided, wherein the fish is of the genus Salmo or Oncorhynchus, and wherein the fish protein hydrolysate comprises at least 1 peptide selected from the group consisting of: Leu-Ala-Phe, Leu-Thr-Phe, Ile-Ile-Phe, Leu-Ala-Tyr, Ile-Ala-Tyr, Val-Phe-Tyr, Tyr-Ala-Tyr, Val-Leu-Trp, Ile-Ala-Trp, Tyr-Ala-Leu and Tyr-Asn-Arg. Methods of making and ... 08/10/06 - 20060178314 - Methods and compositions for treating atheroma, tumors and other neoplastic tissues Compositions comprising motexafin gadolinium, as well as methods for using these compositions in the treatment of brain metastases, are described herein. ... 08/10/06 - 20060178313 - Use of a polypeptide for treatment of pruritus in animals The present invention is directed to a treatment for animal pruritus. One aspect of this invention involves a treatment for animal pruritus comprising one or more polypeptides with an amino acid sequence including KPV (SEQ ID NO: 1), VPK-Ac-CC-Ac-KPV (SEQ ID NO: 5), MEHFRWG (SEQ ID NO: 2), HFRWGKPV (SEQ ... 08/10/06 - 20060178312 - Process for the production of melagatran There is provided a process for the production of melagatran, Formula (I) ex vivo, which process comprises the hydrolysis of a compound of Formula II, wherein R is C1-6 alkyl or a benzylic group, to form, in substantially salt-free form, an intermediate compound of formula II followed by reduction of ... 08/03/06 - 20060172952 - Aza-peptide epoxides Methods for treatment and/or prevention of nerve degeneration in mammals using aza-peptide epoxide caspase inhibitors are provided. Aspects of the present disclosure include aza-peptide epoxide compositions to treat or prevent diseases, for example stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, neuropathies, Huntington's disease, dentatorubropallidoluysian atrophy, spinocerebellar atrophies, spinal bulbar muscular ... 08/03/06 - 20060172951 - Age related macular degeneration and cutaneous signs of mercury toxicity A method is provided for treating age related macular degeneration and Grover's disease by administering a safe and effective amount of a chelation agent to a person who would benefit from such treatment. Of particular effectiveness are chelation agents with sulfur atoms and which through the sulfur bind to mercury. ... 08/03/06 - 20060172950 - Hepatitis c virus inhibitors Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed. ... 07/20/06 - 20060160749 - Tripeptide and tetrapeptide thioethers Tripeptide and tetrapeptide thioethers, pharmaceutical compositions containing them, their pharmaceutical use, and their preparation. The compounds are useful in potentiating the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exerting toxicity in tumor cells, elevating the production of GM progenitors in bone marrow, stimulating the differentiation of bone marrow, ... 07/20/06 - 20060160748 - Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof Disclosed are compounds containing single amino acids, peptides, or derivatives thereof which are selectively delivered to the mitochondria of a cell. Compounds of the invention exhibit antioxidant activity thereby reducing reactive oxygen species in cells. These compounds are useful for inhibiting oxidative stress-induced cell injury or death both in vivo ... 07/20/06 - 20060160747 - Statine derivatives for the treatment of alzheimer's disease ii wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases. ... 07/13/06 - 20060154872 - Hemiasterlin derivatives and uses thereof and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R7, X1, X2, R, Q, and n are as defined herein. ... 07/06/06 - 20060148720 - Use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus According to the invention there is provided the use of melagatran, or a pharmaceutically-acceptable derivative thereof, for the manufacture of a medicament for the treatment of Type I diabetes. ... 07/06/06 - 20060148719 - Tripeptide and tetrapeptide sulfones Tripeptide and tetrapeptide sulfones, pharmaceutical compositions containing them, their pharmaceutical use, and their preparation. The compounds are useful in potentiating the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exerting toxicity in tumor cells, elevating the production of GM progenitors in bone marrow cells, stimulating the differentiation of bone ... 06/29/06 - 20060142205 - Compositions capable of reducing elevated blood urea concentration The invention includes a method of reducing urea concentration in a subject's serum. Such a method comprises administering to the subject (e.g., a mammal such as a human) a composition comprising an oligopeptide (or oligopeptides) having activity in reducing urea concentration in the subject's serum as determined by a mouse ... 06/29/06 - 20060142204 - Pyrrolidine derivatives for use in treating heaptitis c virus infection The present invention relates to novel hepatitis C virus (“HCV”) protease inhibitors or other flavivirus protease inhibitors having the general structure (I) or (II), pharmaceutical compositions containing one or more such inhibitors, methods for preparing such inhibitors, uses of these compounds to treat hepatitis C and related disorders together with ... 06/22/06 - 20060135436 - Peptides and methods for the control of obesity wherein: X1 is an acyl group, Z is amino-2-naphthyl-carboxylic acid or histidine, Q is (D)phenylalanine or p-iodo-(D)phenylalanine, or a pharmacologically acceptable salt, complex or derivative thereof, the peptide derivative having melanocortin-4 receptor agonist activity. ... 06/15/06 - 20060128633 - Colchinol derivatives as vascular damaging agents wherein X is —C(O)—, —C(S)—, —C═NOH, or —CH(R7)— wherein R7 is hydrogen, hydroxy, C1-7alkoxy, —OR8 or —NR8R9 (wherein R8 is a group —Y1R10 (wherein Y1 is a direct bond, —C(O)—, —C(S)—, —S—, —C(O)O—, —C(O)NR11—, —SO2— or —SO2NR12— (wherein R11 and R12, which may be the same or different, each independently ... 06/15/06 - 20060128632 - Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) wherein the substituents are as described in the specification. The inventive compounds are useful as therapeutic agents for the treatment of proliferative disorders, including cancer. ... 06/08/06 - 20060122123 - Antiviral compounds The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. ... 06/01/06 - 20060116327 - Antimicrobial compounds The composition may be used to eliminate and/or reduce microorganisms such as bacteria, viruses, fungi and protozoa. ... 06/01/06 - 20060116326 - Benzothiophene compounds having antiinfective activity are DNA binding compounds exhibiting antibacterial activity. ... 05/25/06 - 20060111302 - Compositions and methods to reduce mutagenesis The present invention provides methods and compositions for said inhibition of drug resistance. In one embodiment, said invention provides methods and compositions for said inhibition of antibiotic resistance. The invention generally involves said administration of achaogens, agents that inhibit said mutational process, to inhibit said evolution of drug resistance. Also, ... 05/18/06 - 20060105960 - New selenohydroxy acids and their derivatives, applications in nutrition, cosmetics and pharmaceutics R7=H, alkyl, natural amino acids, or natural amines. ... 05/11/06 - 20060100159 - Preventing desensitization of receptors Desensitization of receptors that control disease is prevented by inhibiting G-protein receptor kinases. This has applicability, e.g., for patients with heart failure or on a left ventricular heart device or a heart pump after surgery or about to undergo surgery and at high risk for a cardiac event or on ... 05/11/06 - 20060100158 - Statine derivatives for the treatment of alzheimer's disease iii wherein R1, R2, R3, R4, R5, R6, R7 and R8 are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases. ... 05/11/06 - 20060100157 - Novel use of peptide compounds for treating pain in painful diabetic neuropathy The present invention concerns the use of compounds for treating pain in painful diabetic neuropathy, preferably in diabetic distal sensory polyneuropathy. ... 05/04/06 - 20060094664 - Deoxycholic acid derivatives for the treatment of acute dysfunctions of portal and hepatic venous circulation Use of compounds and their salts of formula (I), as reported in the description, in the preparation of drugs for the treatment of acute dysfunctions of portal and hepatic venous circulation. ... 04/27/06 - 20060089313 - Methods and compositions for ameliorating the undesirable effects of chemotherapy In one aspect, the present invention provides chemoprotectant compositions that each comprise at least two of the chemoprotectants disclosed herein. The chemoprotectant compositions of the invention are useful, for example, for ameliorating at least one adverse effect of chemotherapy. In another aspect, the present invention provides methods of ameliorating at ... 04/27/06 - 20060089312 - Protease inhibitors The present invention relates to prodrugs of protease inhibitors, such as inhibitors of proteosome, DPOP IV, FAPα and the like. These “pro-inhibitors” are activated, i.e., cleaved by an “activated protease” to release an active inhibitor moiety in proximity to a “target protease”. The identity of activating protease and target protease ... 04/27/06 - 20060089311 - Agonists and antagonists of ryzn for the treatment of metabolic disorders The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, ... 04/20/06 - 20060084613 - Inhibitors of the ice/ced-3 family of cysteine proteases wherein A, B, R, R1, R1′ p and q are as defined herein. The invention is also directed to pharmaceutical compositions containing one or more of these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the ... 04/13/06 - 20060079462 - Organoselenium compounds for cancer chemoprevention A compound containing an alkylene selenocyanate or an alkylene isoselenocyanate moiety effective to prevent the occurrence or progression of cancer or a precancerous condition. The compound can be provided and administered in the form of a pharmaceutical composition, a cosmetic, a food additive, supplement, or the like. Methods for synthesis ... 04/13/06 - 20060079461 - Treatment of multiple myeloma by inhibition of p38 map kinase The present invention provides a method to treat multiple myeloma by the administration of one or more p38 MAP kinase inhibitor(s). ... 03/30/06 - 20060069037 - Peptide-containing alpha-ketoamide cysteine and serine protease inhibitors This invention relates to peptide-containing α-ketoamide inhibitors of cysteine and serine proteases, methods for making these compounds, and methods for using the same. ... 03/30/06 - 20060069036 - Methods of treatment of inflammation using glutathiones Topical treatment of inflammatory skin diseases by application to affected skin areas of a composition containing glutathione. In the preferred embodiments of the invention, the glutathione is provided in a carrier at very high concentration levels, in the range of 16-70 percent by weight, more preferably 40-60 percent by weight. ... 03/23/06 - 20060063718 - Topical glutathione compositions A composition for treatment of inflammatory skin conditions is provided having a carrier; reduced glutathione; and alpha lipoic acid. The composition preferably contains 25% to 60% by weight glutathione; and 0.5% to 5% by weight alpha lipoic acid. The composition is useful for topical treatment of psoriasis and other inflammatory ... 03/09/06 - 20060052312 - Paclitaxel hybrid derivatives Methods and compositions for treating cancer patients that include administering at least one or more hybrid derivatives of paclitaxel that simultaneously display improved aqueous solubility, chemical stability under physiological conditions, a decreased liability toward multi-drug resistance, and in certain instances enhanced selective toxicity toward cancer cells compared to normal cells. ... 03/09/06 - 20060052311 - Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) wherein the substituents are as described in the specification. The inventive compounds are useful as therapeutic agents for the treatment of proliferative disorders, including cancer. ... 02/23/06 - 20060040870 - Enhancement of apoptosis by caspase-9 inhibitors The present invention provides methods for inducing apoptosis in a tumor cell by contacting the cell with a caspase-9 inhibitor. ... 02/23/06 - 20060040869 - Pharmaceutically useful compounds A compound of formula (I) or (II): wherein A is hydrogen or CR1R2; Y and Z are each, independently, hydrogen or a halogen; X is —NR4R5, or R7; R1 is hydrogen, or a substituted or unsubstituted alkyl or alkenyl group containing 1-4 carbon atoms; when X is —NR4R5, R2 is ... 02/09/06 - 20060030533 - Compounds for enzyme inhibition Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. ... 01/26/06 - 20060019905 - Hepatitis c inhibitor peptide analogs wherein R1, R2, R3, R4, R5, Y, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease. ... 01/19/06 - 20060014698 - Nebulized pharmaceutical compositions for the treatment of bronchial disorders The present invention provides methods and pharmaceutical compositions for the treatment of bronchial disorders by inhalation therapy. In various embodiments, the active ingredient of the pharmaceutical compositions is one or more of a sulfated pentasaccharide and a peptidomemtic of a tripeptide. In various embodiments, the active ingredient of the pharmaceutical ... 01/12/06 - 20060009396 - Novel heteroaryl peptidomimetics as thrombin receptor antagonists The invention is directed to novel heteroaryl peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, angiogenesis and related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted heteroaryl peptidomimetics ... 01/12/06 - 20060009395 - Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm This invention relates generally to dipeptides and tripeptides and to methods for pharmaceutical treatment of mammals using analogs of such dipeptides and tripeptides. More specifically, the invention relates to tripeptides and their analogs, to pharmaceutical compositions containing such dipeptides and tripeptides and to methods of treatment of mammals using such ... 01/12/06 - 20060009394 - Process for manufacturing a glutamic acid derivative and a pyroglutamic acid derivative and a novel intermediate in the manufacture thereof Glutamic acid derivatives, in particular monatin, may be conveniently prepared by alkylating a 4-protected hydroxyl pyroglutamic acid derivative with an alkylating agent to prepare a 4-protected hydroxyl-4-alkylglutamic acid derivative, followed by the steps of hydrolysis and deprotection. The 4-protected hydroxyl pyroglutamic acid derivative is easy to produce from hydroxyproline. The ... 01/05/06 - 20060003943 - Protease enzyme inhibitors wherein [Poly] is a water-soluble, non-peptidic polymer component, L is an optionally present linking group, and RCHO is a substrate capable of interacting with one or more protease enzymes to reversibly inhibit said enzyme, and wherein said substrate comprises a peptide or peptide-like aldehyde. The index z is 0 when ... 01/05/06 - 20060003942 - Combinations for hcv treatment The present invention relates to co-administering a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The combination acts by interfering with the life cycle of the hepatitis C virus and is therefore useful as an antiviral therapy. As such, the combination may be used for treating ... 12/29/05 - 20050288231 - Biologically active peptides as glutamate receptor inhibitors The present invention relates to biologically active peptides derived from the neurite outgrowth-promoting domain of luminin-1, i.e. the γ1-chain of laminin-1. These peptides include the decapeptide RDIAEIIKDI (SEQ ID NO: 1) and the truncated peptides derived therefrom comprising the biologically active domain thereof, the tripeptide KDI. The invention is directed ... 12/22/05 - 20050282757 - Peptide boronic acid compounds useful in anticoagulation A method for preventing thrombosis in a setting where rapid onset and/or rapid offset of anticoagulation is required, comprising administering a compound selected from the group consisting of boronic acids which have a neutral thrombin P1 domain linked to a hydrophobic moiety capable of binding to the thrombin S2 and ... 12/08/05 - 20050272665 - Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters and a process for the preparation of such compounds are disclosed. ... 12/08/05 - 20050272664 - Methods for inhibiting angiogenesis and or lymphangiogenesis Proprotein convertase inhibitor has been found to block proteolytic processing and activation of VEGF-C and VEGF-D and inhibit angiogenesis and/or lymphangiogenesis. Method and composition are disclosed for inhibiting angiogenesis and/or lymphangiogenesis, and for treating conditions associated with excessive angiogenesis, such as tumors and/or retinopathies, as well as conditions associated with ... 12/08/05 - 20050272663 - Novel substituted prolines as inhibitors of hepatitis c virus ns3 serine protease The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. ... 12/01/05 - 20050267041 - Tetrapeptide derivative crystals The invention provides crystals of N2-(N,N-dimethyl-L-valyl)-N-[(1S, 2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-[(S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide or salts thereof which possess potent antitumor activity and methods for their preparation. ... 12/01/05 - 20050267040 - Hepatitis c virus inhibitors wherein A, R2, R3, R′, B and Y are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed. ... 11/24/05 - 20050261202 - Sensitization to another anticancer therapy and/or amelioration of a side effect of another anitcancer therapy by treatment with a gst-activated anticancer compound A method of sensitizing a mammal, especially a human, to another anticancer therapy by administering a sensitizing effective amount of a GST-activated anticancer compound. A method of ameliorating a side effect of another anticancer therapy in a mammal, especially a human, by administering an ameliorating effective amount of a GST-activated ... 11/24/05 - 20050261201 - Method of reducing c-reactive protein using growth hormone secretagogues The present invention relates to a method of reducing C-reactive protein in a subject in need of treatment thereof, wherein the subject is at risk of having or the subject has already had a vascular event or suffering from an inflammatory disease or disorder. In one embodiment, the vascular event ... 11/24/05 - 20050261200 - Tri-peptide hepatitis c serine protease inhibitors which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned ... 11/24/05 - 20050261199 - Pharmaceutical composition comprising a retro-iverso isomer peptide The present invention provides a pharmaceutical composition comprising a peptide selected from the group consisting of D-Pro D-Tyr D-Val D-Val, D-Pro D-Tyr D-Val, and D-Leu D-Thr D-Val as an active component. The composition of the present invention has great efficacy in lowering serum triglyceride levels. ... 11/24/05 - 20050261198 - Sulfur-containing proanthocyanidin oligomer compositon and process for producing the same Provided are: method of producing a sulfur-containing proanthocyanidin oligomer by reducing the molecular weight of proanthocyanidin in plants so that they can be readily absorbed through the intestine of an organism; and a health food composition and a pharmaceutical composition which contain the resultant sulfur-containing proanthocyanidin oligomer as an active ... 11/17/05 - 20050256058 - Propenoyl hydrazides The present disclosure provides compositions for inhibiting proteases, methods for synthesizing the compositions, and methods of using the disclosed protease inhibitors. Aspects of the disclosure include a peptidyl propenoyl hydrazide compositions that inhibit proteases, for example cysteine proteases, either in vivo or in vitro. ... 11/17/05 - 20050256057 - Protein hydrolysate rich in tripeptides The present invention describes a protein hydrolysate which is rich in tripeptides whereby the tripeptides are rich in proline at one end of the peptide. ... 11/10/05 - 20050250705 - Spray-dried powder comprising at least one 1,4 o-linked saccharose-derivative and methods for their preparation The present invention relates to a spray-dried powder and method for its manufacture. A spray dried powder containing a pharmaceutical active substance and one or more 1,4 O-linked saccharose derivatives chosen from the compounds: 1,4 O-linked D-gal-saccharose (lactosucrose), 1,4 O-linked D-glu-saccharose (glucosyl sucrose) or 1,4 O-linked glu-glu-saccharose (maltosyl sucrose). Preferred ... 11/10/05 - 20050250704 - Powder comprising new compositions of oligosaccharides and methods for their preparation The present invention concerns powders containing a pharmaceutical active substance and a combination of excipients comprising at least one 1,4 O-linked saccharose derivative selected from the compounds: 1,4 O-linked D-Gal-saccharose (lactosucrose), 1,4 O-linked D-Glu-saccharose (glucosyl sucrose), or 1,4 O-linked Glu-Glu-saccharose (maltosyl sucrose) in combination with at least one further excipient. ... 11/10/05 - 20050250703 - Antioxidant constituents An object of the present invention is to provide an antioxidant composition that is effective in the living body against active oxygen species produced in the body. The present invention provides an antioxidant composition having the effect of suppressing three active oxygen species, i.e. hypochlorite radicals, hydroxyl radicals, and peroxynitrite ... 11/10/05 - 20050250702 - Controlling availability or activity of proteins by use of protease inhibitors or receptor fragments The invention relates to the field of proteins, more specifically to those proteins that are located on the surface of the cell. The invention, among other things, provides an inhibitor or pharmaceutical composition capable of inhibiting down-regulation of a cell surface receptor. The invention provides a method to control or ... 10/27/05 - 20050239712 - Pharmaceutically active compound wherein A is α-OH or β-OH, B is α-H or β-H, C is —H, α-OH or β-OH, or B and C together form a double bond, D is —H, α-OH or β-OH, E is —H, α-OH or β-OH, -G- is a side chain moiety, —NH-J is selected from (i) a ... 10/20/05 - 20050233975 - Enone cancer therapeutics Described herein are new enone derivatives and conjugates. Additionally, methods for synthesizing these new enones are also disclosed. These compounds can be employed in cancer therapy. ... 10/20/05 - 20050233974 - Treating infectious diseases using ice inhibitors This invention relates to methods and compositions for treating infectious and other diseases, particularly of the eye, by administering an ICE inhibitor. This invention also relates to methods for treating injuries, allergies, chemical irritations, or burns of the eye by administering an ICE inhibitor. ... 10/20/05 - 20050233973 - Tri-peptides for antidepressant applications Provided are methods of treatment of neurological and neurobehavioral disorders, including antidepressants for use in treatment of depression and related disorders, utilizing pharmaceutical preparations including a manufactured peptide having the formula pGlu-R1-Pro, wherein R1 is Glu, Phe, Leu, Tyr, Lys or Val, and preferably Gly, Lys, Leu or Val, or ... 10/06/05 - 20050222046 - Pharmaceutical preparations of glutathione and methods of administration thereof A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed. ... 10/06/05 - 20050222045 - Novel derivatives of 2-hydroxytetrahydrofuran and their use as medicaments R represents H, alkyl or —CO—R19, R19 representing alkyl. These compounds have a calpain inhibiting activity and/or an activity which traps the reactive oxygen species and can be used for preparing a medicament intended to treat the inflammatory and immunological diseases, cardio-vascular and cerebro-vascular diseases, disorders of the central or ... 09/29/05 - 20050215486 - Inhibitors of serine proteases, particularly hcv ns3-ns4a protease or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions ... 09/29/05 - 20050215485 - Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation The present invention relates to a stable liquid preparation comprising a camptothecin derivative which is prepared by binding a compound of the formula [I]: wherein R1 is a substituted or unsubstituted lower alkyl group, X1 is a group of the formula: —NHR2 (R2 is a hydrogen atom or a lower ... 09/15/05 - 20050203028 - Method of preparing peptide The present invention provides a method of preparing an intermediate for LHRH antagonists, which requires fewer steps than conventional methods and provides the intermediate in high yield and high purity. ... 09/08/05 - 20050197300 - Microdose therapy Methods for treating vascular conditions associated with localized imbalance in vascular tone, which are hypothesized to be largely due to elevated endothelin (ET) are provided. The methods involve administration of nitric oxide (NO), agents which are able to provide NO, such as NO donors, agents which activate guanyl cyclase, such ... 09/08/05 - 20050197299 - Peptidomimetic protease inhibitors The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds ... 09/01/05 - 20050192229 - Topical glutathione treatments Topical treatment of psoriasis and other inflammatory skin diseases by application to affected skin areas of a composition containing glutathione. In the preferred embodiments of the invention, the glutathione is provided in a carrier at very high concentration levels, in the range of 16-70 percent by weight, more preferably 40-60 ... 09/01/05 - 20050192228 - Tripeptide derivatives for the treatment of neurodegenerative diseases The invention relates to the use of specific tripeptides for the treatment of neurodegenerative diseases. The tripeptide derivatives satisfy the following formula (I): wherein X represents OH, (C1-5)alkoxy, NH2, NH—C1-5-alkyl, N(C1-5alkyl)2; R1 is a residue derived from any of the amino acids Phe, Tyr, Trp, Pro, each of which may ... 08/25/05 - 20050187166 - C-nitroso compounds and use thereof A C-nitroso compound having a molecular weight ranging from 225 to 1,000 (from 225 to 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon, which is obtained by nitrosylation of a carbon acid having a pKa less than about 25, is ... 08/25/05 - 20050187165 - Hepatitis c virus inhibitors wherein R1, R2, R3, R4, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed. ... 08/11/05 - 20050176650 - Stable parenteral formulation of levomepromazine and a method for stabilizing said formulation The present invention relates to stabilized formulations for parenteral administration comprising a therapeutically effective amount of levomepromazine or a pharmaceutically acceptable salt thereof, and selected stabilizers in an amount effective to stabilize said formulation, to stable terminally sterilized levomepromazine formulations, to methods stabilizing pharmaceutical formulations comprising levomepromazine, and to methods ... 08/11/05 - 20050176649 - Iap binding peptides and assays for identifying compounds that bind iap Assays are disclosed for identifying peptides and peptidomimetics for promoting apotosis in cells, through a pathway involving the Inhibitor of Apoptosis Proteins (IAPs), exemplified by XIAP, and the mitochondrial protein Smac/DIABOLO (hereinafter Smac) and homologs thereof. Also disclosed are IAP-binding peptides and peptidomimetics identified through the use of the assay. ... 08/04/05 - 20050171022 - Proteaseome inhibitors for the treatment of herpesviridae infected individuals The present invention relates to the use of a substance or composition comprising one or more proteasome inhibitors for the manufacture of a medicament for the treatment of an individual infected with a virus selected from the group comprising varicella zoster virus, human cytomegalovirus, human herpesvirus 6 and 7 and ... 07/21/05 - 20050159362 - Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia The present invention provides compositions adapted to enhance reverse cholesterol transport in mammals. The compositions are suitable for oral delivery and useful in the treatment and/or prevention of disease conditions associated with hypercholesterolemia. ... 07/14/05 - 20050153901 - Crystalline forms There is provided EtO2C—CH2—(R)Cgl-Aze-Pab-OH, or a pharmaceutically-acceptable salt thereof, in a form which is substantially crystalline. It has been found that crystalline forms of EtO2C—CH2—(R)Cgl-Aze-Pab-OH have a high chemical and solid state stability when compared to amorphous forms of the compound. ... 07/14/05 - 20050153900 - Novel inhibitors of hepatitis c virus ns3/ns4a serine protease The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. ... 06/30/05 - 20050143316 - Hepatitis c virus inhibitors wherein R1, R2, R3, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed. ... 06/30/05 - 20050143315 - Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy The present invention provides the use of acryloyl distamycin derivatives, in particular α-bromo- or α-chloro-acryloyl distamycin derivatives, in combination with radiotherapy, for the treatment of tumors. ... 06/23/05 - 20050137140 - Inhibitors of serine proteases, particularly hcv ns3-ns4a proteases or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions ... 06/23/05 - 20050137139 - Inhibitors of serine proteases, particularly hcv ns3-ns4a protease The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these ... 06/16/05 - 20050130906 - Amelioration of macular degeneration and other ophthalmic diseases Methods for the treatment or prevention of a number of ocular diseases or disorders are disclosed. In particular, methods are disclosed for the amelioration of macular degeneration, diabetic retinopathy and other retinopathies, as well as uveitis, presbyopia, dry eye, glaucoma, blepharitis and rosacea of the eye. The methods comprise administration ... 06/16/05 - 20050130905 - Extended storage of reduced glutathione solutions A method of storing solutions of reduced glutathione for extended periods of time, by dissolving reduced glutathione in an aqueous medium having a pH of between 5.0 and 8.0 to produce a reduced glutathione solution; reducing the temperature of the reduced glutathione solution to a predetermined temperature which is sufficiently ... 06/16/05 - 20050130904 - Therapeutic compositions A method is provided for the preparation of compounds of the formula (R1)(R2)NC(═X)S(O)nR3 or (R1)(R2)NC(═X)OS(O)nR3, wherein R1, R2 and R3, X and n have any of the meanings defined in the specification. A method is also provided for the detection and quantitation of compounds of the formula (R1)(R2)NC(═X)OS(O)nR3. A method ... 06/09/05 - 20050124553 - Peptide compositions for treatment of sexual dysfunction or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, m and n are as defined. Further provided are methods for treatment of sexual dysfunction, including erectile dysfunction and female sexual dysfunction, and combination drugs and method of use thereof, including a peptide of the invention and ... 06/09/05 - 20050124552 - Use of glutathione synthesis stimulating compounds in reducing insulin resistance There is provided a method of reducing insulin resistance in a mammalian patient comprising selecting a patient suffering from insulin resistance and administering a compound which increases hepatic glutathione and a compound which increases hepatic nitric oxide. ... 06/02/05 - 20050119189 - Inhibitors of serine proteases, particularly hcv ns3-ns4a protease or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising ... ### FreshPatents.com Support |